Role and limitations of 18F-FDG positron emission tomography (PET) in the management of patients with pancreatic lesions;Intérêt et limites de la tomographie par émission de positons au 18F-FDG couplée au scanner dans la prise en charge des patients atteints de tumeurs du pancréas

Gastroenterologie Clinique et Biologique

Volumn 34, Issue 8-9, 2010, Pages 465-474

  Pery, C ^a   Meurette, G ^a   Ansquer, C ^a   Frampas, E ^a   Regenet, N ^a  

^a HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT;

CANCER DIAGNOSIS; CHRONIC PANCREATITIS; COMPUTER ASSISTED TOMOGRAPHY; DIABETES MELLITUS; ENDOCRINE TUMOR; METASTASIS; PANCREAS ADENOCARCINOMA; PANCREAS DISEASE; POSITRON EMISSION TOMOGRAPHY; SHORT SURVEY; ADENOCARCINOMA; CANCER STAGING; CYSTADENOCARCINOMA; CYSTADENOMA; ECONOMICS; HUMAN; INSULINOMA; METHODOLOGY; PANCREAS TUMOR; PANCREATITIS; PATHOLOGY; PROGNOSIS; REVIEW; SCINTISCANNING;

ADENOCARCINOMA; CYSTADENOCARCINOMA; CYSTADENOMA; FLUORODEOXYGLUCOSE F18; HUMANS; INSULINOMA; NEOPLASM METASTASIS; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PANCREATITIS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 77957135552     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gcb.2009.04.014     Document Type: Short Survey

References (50)

1. Sperti C., Pasquali C., Chierichetti F., Liessi G., Ferlin G., Pedrazzoli S. F-18-fluorodeoxyglucose positron emission tomography in differentiating malignant from benign pancreatic cysts: a propective study. J Gastrointest Surg 2005, 9:22-29.
2. Sperti C., Pasquali C., Chierichetti F., Ferronato A., Decet G., Pedrazzoli S. 18-fluorodeoxyglucose positron emission predicting survival of patients with pancreatic carcinoma. J Gastrointest Surg 2003, 7:953-959.
3. Yoshioka M., Sato T., Furuya T., Shibata S., Andoh H., Asanuma Y., et al. Positron emission tomography with 2-deoxy-2-fluoro-D-glucose for diagnosis of intraductal papillary mucinous tumor of the pancreas with parenchymal invasion. J Gastroenterol 2003, 38:1189-1193.
4. Mansour J.C., Schwartz L., Pandit-Taskar N., D'Angelica M., Fong Y., Larson S.M., et al. The utility of F-18-fluorodeoxyglucose whole body PET imaging for determining malignancy in cystic lesions of the pancreas. J Gastrointest Surg 2006, 10:1354-1360.
5. Van Kouwen M.C., Jansen J.B., Van Goor H., et al. FDG-PET is able to detect pancreatic carcinoma in chronic pancreatitis. Eur J Nucl Med Mol Imaging 2005, 32:399-404.
6. Friess H., Langhans J., Ebert M., Beger H.G., Stollfuss J., Reske S.N., et al. Diagnosis of pancreatic cancer by 2-fluoro-2-deoxy-D-glucose positron emission tomography. Gut 1995, 36:771-777.
7. Nakamoto Y., Sakahara H., Higashi T., Saga T., Sato N., Okazaki K., et al. Autoimmune pancreatitis with F-18 fluoro-2-deoxy-D-glucose PET findings. Clin Nucl Med 1999, 24:778-780.
8. Buck A.C., Schirrmeister H.H., Guhlmann C.A., Diederichs C.G., Shen C., Buchmann I., et al. Ki-67 immunostaining in pancreatic cancer and chronic active pancreatitis: does in vivo FDG uptake correlate with proliferative activity?. J Nucl Med 2001, 42:721-725.
9. Torisani J., Buscail L. Mécanismes moléculaires de la cancérogenèse pancréatique. Ann Pathol 2002, 22:349-355.
10. Maire F., Voitot H., Aubert A., Palazzo L., O'Toole D., Couvelard A., et al. Intraductal papillary mucinous neoplasms of the pancreas: performance of pancreatic fluid analysis for positive diagnosis and the prediction of malignancy. Am J Gastroenterol 2008, 103:2871-2877.
11. Heinrich S., Goerres G.W., Schäfer M., Sagmeister M., Bauerfeind P., Pestalozzi B.C., et al. Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness. Ann Surg 2005, 242:235-243.
12. 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?. Acta Gastroenterol Belg 2007, 70:331-338.
13. 18F-FDG positron emission tomography CT (FDG PET-CT) in the management of pancreatic cancer: initial experience in 12 patients. J Gastrointest Liver Dis 2008, 17:173-178.
14. 18F-fluorodeoxyglucose positron emission tomography imaging in surgery for pancreatic cancer. World J Gastroenterol 2008, 14:64-69.
15. Bipat S., Phoa S.S., Van Delden O.M., Bossuyt P.M., Gouma D.J. Ultrasonography, computed tomography and magnetic resonance imaging for diagnosis and determining resectability of pancreatic adenocarcinoma: a meta-analysis. J Comput Assist Tomogr 2005, 29:438-445.
16. Bang S., Chung H.W., Park S.W., Chung J.B., Yun M., et al. The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography n the differential diagnosis, staging, and response evaluation after concurrent chemradiotherapy for pancreatic cancer. J Clin Gastroenterol 2006, 40:923-929.
17. Nishiyama Y., Yamamoto Y., Yokoe K., Monden T., Sasakawa Y., et al. Contribution of whole body FDG-PET to the detection of distant metastasis in pancreatic cancer. Ann Nucl Med 2005, 19:491-497.
18. 18F-fluorodeoxyglucose positron emission tomography with preoperative evaluation of patients with pancreatic masses. Pancreas 2000, 20:109-116.
19. Thésaurus national de cancérologie digestive. Société nationale française de gastroentérologie 2008; www.snfge.asso.fr.
20. 18F-fluorodeoxyglucose positron emission tomography and the prognosis of patients with pancreatic adenocarcinoma. Cancer 1997, 79:695-699.
21. 18F-fluorodeoxyglucose positron emission tomography for patients with pancreatic cancer. Int J Oncol 2001, 19:53-58.
22. Ducreux M., Taieb J., Boige V. La tomographie par émission de positons en cancérologie digestive. Gastroenterol Clin Biol 2003, 27:71-78.
23. Brucher B.L., Weber W., Bauer M. Neoadjuvant chemotherapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg 2001, 233:300-309.
24. Flamen P., Van Custem E., Lerut A. Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced esophageal cancer. Ann Oncol 2002, 13:361-368.
25. Rose D.M., Delbeke D., Beauchamp R.D., Chapmann W.C., Sandler M.P., Sharp K.W., et al. 18-fluorodeoxyglucose positron emission tomography in the management of patients with suspected pancreatic cancer. Ann Surg 1999, 229:729-738.
26. Maisey N.R., Webb A., Flux G.D., Padhani A., Cunningham D.C., Ott R.J., et al. FDG-PET in the prediction of survival of patients with cancer of the pancreas: a pilot study. Br J Cancer 2000, 83:287-293.
27. Ruf J., Lopez Hänninen E., Oettle H., Plotkin M., Pelzer U., et al. Detection of recurrent pancreatic cancer: comparison of FDG-PET with CT/MRI. Pancreatology 2005, 5:266-272.
28. Malka D., Hammel P., Maire F., Rufat P., Madeira I., Pessione F., et al. Risk of pancreatic adenocarcinoma in chronic pancreatitis. Gut 2002, 51:849-852.
29. Lowenfels A.B., Maisonneuve P., Whitcomb D.C. Risk factors for cancer in hereditary pancreatitis. Med Clin North Am 2000, 84:565-573. International Hereditary Pancreatitis Study Group.
30. 18F]fluoro-2-deoxy-D-glucose for the differentiation of chronic pancreatitis and pancreatic cancer. Br J Surg 1999, 86:194-199.
31. Zimny M., Bares R., Fass J., Adam G., Cremerius U. Fluorine-18-fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: a report of 106 cases. Eur J Nucl Med 1997, 24:678-682.
32. Lévy P., Hammel P., Ruszniewski P. Diagnostic challenge in autoimmune pancreatitis: beware of shipwreck. Gut 2008, 57:1646-1647.
33. Ozaki Y., Oguchi K., Hamano H., Arakura N., Muraki T., et al. Differentiation of autoimmune pancreatitis from suspected pancreatic cancer by fluorine-18-fluorodeoxyglucose positron emission tomography. J Gastroenterol 2008, 43:144-151.
34. Nakajo M., Jinnouchi S., Fukukura Y., Tanabe H., Tateno R., et al. The efficacy of whole-body FDG-PET or PET/CT for autoimmune pancreatitis and associated extrapancreatic autoimmune lesions. Eur J Nucl Med Mol Imaging 2007, 34:2088-2095.
35. Sperti C., Pasquali C., Chierichetti F., Liessi G., Ferlin G., Pedrazzoli S. Value of 18-fluorodeoxyglucose positron emission tomography in the management of patients with cystic tumors of the pancreas. Ann Surg 2001, 234:675-680.
36. Sperti C., Bissoli s, Pasquali C., Frison L., Liessi G., Chierchetti F., et al. 18-fluorodeoxyglucose positron emission tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas. Ann Surg 2007, 246:932-939.
37. 18-FDG-PET in managing pancreas intraductal papillary mucinous neoplasms: preliminary results. J Exp Clin Cancer Res 2008, 27:10.
38. Sato M., Takasaka I., Okumura T., Shioyama Y., Kawasaki H. High F-18 fluorodeoxyglucose accumulation in solid pseudopapillary tumors of the pancreas. Ann Nucl Med 2006, 20:431-436.
39. Lee J.K., Tyan Y.S. Detection of a solid pseudopapillary tumor of the pancreas with F-18 FDG positron emission tomography. Clin Nucl Med 2005, 30:187-188.
40. Cadiot G., Mignon M., Gresze Stratégie diagnostique des tumours duodénopancréatiques. Gastroenterol Clin Biol 2003, 27:6-14.
41. Dromain C., Baudin E. Stratégie d'explorations radiologiques pour le bilan d'extension et la surveillance des tumeurs endocrines. Bull Cancer 2006, 93:1183-1189.
42. Adams S., Baum R., Rink T., Schumm-Dräger P.M., Usadel K.H., Hör G., et al. Limited value of fluorine-18-fluodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur J Nucl Med 1998, 25:79-83.
43. 18F-FDG PET/CT. Ann Nucl Med 2008, 22:133-137.
44. 18F-fluorodeoxyglucose positron emission tomography detect tumors with poor prognosis and aggressive behavior?. World J Surg 1998, 22:588-592.
45. Nakamoto Y., Higashi T., Sakahara H., Tamaki N., Itoh K., et al. Evaluation of pancreatic islet cell tumors by fluorine-18-fluorodeoxyglucose positron emission tomography: comparison with other modalities. Clin Nucl Med 2000, 25:115-119.
46. Proye C., Verin P. Imagerie préopératoire des insulinomes de l'adulte. Fiabilité-rentabilité. Ann Chir 1988, 42:391-393.
47. 18F-DOAP) positron emission tomography as a tool to localize an insulinoma or β-cell hyperplasia in adults patients. J Clin Endocrinol Metab 2007, 92:1237-1244.
48. Montravers F., Grahek D., Kerrou K., Ruszniewski P., de Beco V., et al. Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors?. J Nucl Med 2006, 47:1455-1462.
49. Diederichs C.G., Staib L., Glatting G., Beger H.G., Reske S.N. FDG PET: elevated plasma glucose reduces both uptake and detection rate of pancreatic malignancies. J Nucl Med 1998, 39:1030-1033.
50. Bourguet P., Planchamp F., Monteil J., et al. Recommandations pour la pratique clinique: utilisation de la TEP-FDG dans les cancers de l'œsophage, de l'estomac, du côlon et du rectum, du canal anal, de l'intestin grêle, du pancréas et des voies biliaires, du foie et les tumeurs endocrines (système digestif). Bull Cancer 2006, 93(12):1228-1232.